Silex Systems Limited
2.10
EUR
-0.10
(-4.55%)
Silex Systems Limited
GETTEX:RW4
(Gettex)
Recent
price
2.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Silex Systems Limited specializes in the research, development, commercialization, and licensing of advanced laser-based enrichment technology known as SILEX. Its core products and services include uranium enrichment for nuclear power applications; silicon enrichment for silicon-based quantum computing technology; and medical isotope enrichment aimed at cancer therapy innovations. The company operates through three segments: Silex Systems, which focuses on the core laser enrichment technology; Translucent, which develops advanced materials including power FET devices and substrates for high-efficiency solar cells; and Silex USA, which supports operations and commercial partnerships primarily in the United States and the United Kingdom. It also sells cREO technology as part of its portfolio. Silex provides these technology solutions primarily in Australia, the United States, and the United Kingdom. Founded in 1987 and headquartered in Lucas Heights, Australia, the company targets strategic markets including nuclear power, solar power, quantum computing, and medical sectors. In recent developments, Silex Systems commenced its Q-Si Production Project in August 2023 focused on silicon enrichment for quantum computing applications. The company remains engaged in advancing its SILEX uranium enrichment technology through its joint venture Global Laser Enrichment (GLE), with ongoing commercial maturation programs. In 2025, Silex also announced performance rights incentives aligning executives with long-term company goals, following shareholder approval at the 2025 Annual General Meeting. The company continues to develop innovative medical isotope separation technology (MIST) and explores new applications for its laser enrichment technology across different isotope markets, supporting growth and diversification in its product offering. Silex generates revenue through licensing agreements, technology sales, and collaborative ventures, with notable geographic sales distributions in the US and UK markets. The company maintains focus on commercializing disruptive technology in key energy and technology sectors and actively pursues strategic partnerships and operational expansions to enhance market presence. Its proprietary SILEX laser enrichment technology remains central to its business strategy, aiming to provide cost-efficient, scalable isotope enrichment solutions with applications in nuclear energy, quantum computing, and medical industries. Silex Systems Limited is publicly listed on the Australian Securities Exchange under the ticker SLX and trades on OTCQX as SILXY. The company employs a lean workforce focused on technology innovation and commercialization. It holds itself as a world leader in laser enrichment technology with a significant emphasis on research and development to support future commercial applications globally. The company’s strategic portfolio and ongoing projects position it at the forefront of emerging high-tech sectors involving isotope enrichment and advanced materials development.
Company News
Silex Systems Limited (SILXY) Shareholder/Analyst Call Transcript
Is Cameco Stock a Buy Now?
Energous (NASDAQ:WATT) & Silex Systems (OTCMKTS:SILXY) Financial Review
Michael Goldsworthy Sells 650,000 Shares of Silex Systems (ASX:SLX) Stock
Silex Systems: Next-Gen Technology In The Uranium Industry
Silex Systems (OTCMKTS:SILXY) Stock Price Down 2.1% – Time to Sell?
Silex Systems (OTCMKTS:SILXY) Trading Down 7.4% – Here’s What Happened